TD Asset Management Inc Buys 24,000 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

TD Asset Management Inc increased its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 18.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 154,338 shares of the company’s stock after buying an additional 24,000 shares during the quarter. TD Asset Management Inc owned 0.28% of Vera Therapeutics worth $5,584,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Ameritas Investment Partners Inc. increased its holdings in Vera Therapeutics by 20.8% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock valued at $172,000 after purchasing an additional 688 shares in the last quarter. Cetera Advisors LLC acquired a new stake in Vera Therapeutics during the 1st quarter valued at $235,000. Capstone Investment Advisors LLC acquired a new stake in shares of Vera Therapeutics in the 1st quarter valued at $248,000. Pale Fire Capital SE acquired a new stake in shares of Vera Therapeutics in the 4th quarter valued at $252,000. Finally, New York State Common Retirement Fund increased its stake in shares of Vera Therapeutics by 55.5% in the 4th quarter. New York State Common Retirement Fund now owns 17,491 shares of the company’s stock valued at $269,000 after buying an additional 6,244 shares during the period. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Stock Up 0.1 %

NASDAQ:VERA opened at $37.57 on Thursday. Vera Therapeutics, Inc. has a 12-month low of $9.24 and a 12-month high of $50.78. The company has a quick ratio of 21.43, a current ratio of 21.43 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $2.06 billion, a P/E ratio of -18.33 and a beta of 0.99. The stock’s fifty day simple moving average is $36.95 and its 200-day simple moving average is $39.39.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.06). Equities research analysts expect that Vera Therapeutics, Inc. will post -2.59 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on VERA shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $107.00 target price on shares of Vera Therapeutics in a research note on Friday, September 6th. JPMorgan Chase & Co. lifted their target price on Vera Therapeutics from $62.00 to $72.00 and gave the company an “overweight” rating in a research note on Tuesday, September 3rd. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Vera Therapeutics presently has a consensus rating of “Buy” and an average price target of $51.75.

Insiders Place Their Bets

In other Vera Therapeutics news, CEO Marshall Fordyce sold 14,471 shares of Vera Therapeutics stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $39.76, for a total transaction of $575,366.96. Following the transaction, the chief executive officer now directly owns 322,667 shares in the company, valued at $12,829,239.92. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 21.70% of the company’s stock.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.